推荐产品
等級
pharmaceutical primary standard
API 家族
fexofenadine
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
Cl[H].CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4
InChI
1S/C32H39NO4.ClH/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);1H
InChI 密鑰
RRJFVPUCXDGFJB-UHFFFAOYSA-N
基因資訊
human ... HRH1(3269)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Fexofenadine hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets
- Fexofenadine Hydrochloride Capsules
- Fexofenadine Hydrochloride Tablets
生化／生理作用
非索非那定是一种非镇静性 H1 组胺受体拮抗剂。
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Erik Sjögren et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 57, 214-223 (2013-10-01)
The pharmacokinetics (PK) of fexofenadine (FEX) in pigs were investigated with the focus on exploring the interplay between hepatic transport and metabolism when administered intravenously (iv) alone or with verapamil. The in vivo pig model enabled simultaneous sampling from plasma
Takayo Haruna et al.
Pharmacology, 95(1-2), 95-103 (2015-02-28)
We have previously reported that S-777469 [1-([6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]amino)-cyclohexanecarboxylic acid], a novel cannabinoid type 2 receptor (CB2) agonist, significantly suppressed compound 48/80-induced scratching behavior in mice in a dose-dependent manner when it was administered orally. Here, we demonstrated that the inhibitory effects
Jung Yeon Kim et al.
Biomedical chromatography : BMC, 29(3), 465-474 (2014-08-01)
The purpose of this study was to develop and validate an ultra-performance liquid chromatography method for simultaneous analysis of 20 antihistamines (illegal additives) in dietary supplements. The limits of detection and quantitation of the method ranged from 1.5 to 2.5
Shigeru Hishinuma et al.
Biochemical pharmacology, 91(2), 231-241 (2014-07-30)
Differential binding sites for first- and second-generation antihistamines were indicated on the basis of the crystal structure of human histamine H1 receptors. In this study, we evaluated differences between the thermodynamic driving forces of first- and second-generation antihistamines for human
Yoshiyuki Shirasaka et al.
Pharmaceutical research, 31(8), 2035-2043 (2014-02-20)
OATP2B1-mediated grapefruit juice (GFJ)-drug interactions are substrate-dependent; for example, GFJ ingestion significantly reduces bioavailability of fexofenadine, but not pravastatin. In the present study, we aimed to establish whether this observation can be explained by the presence of multiple binding sites
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门